, Volume 31, Issue 1, pp 41–45 | Cite as

Reduction of plasma 1,5-anhydroglucitol (1-deoxyglucose) concentration in diabetic patients

  • T. Yamanouchi
  • H. Akanuma
  • T. Nakamura
  • I. Akaoka
  • Y. Akanuma


The plasma concentration of 1,5-anhydro-D-glucitol (AG)(1-deoxyglucose) is known to decrease in diabetic patients. In order to evaluate the usefulness of this polyol as a diabetic marker, we examined the specificity of the plasma AG reduction in various diseases: the plasma AG level was determined in 108 newly diagnosed diabetic patients, 229 normal subjects and 200 patients with various other disorders. The mean plasma AG concentration in diabetes mellitus was 1.9±1.8 μg/ml (mean±SD), which was definitely lower than that in healthy subjects and patients with other diseases including some metabolic and hormonal diseases (mean value range: 13.4–28.3 μg/ml). Only the “malignancies” group showed statistically different mean values from that in normal subjects; however, these values were much higher than those of diabetic patients. The AG concentration seemed to be relatively low in some severe by uraemic patients, but is likely to be little influenced by the glomerular filtration rate. Upon adjustment for sex and age, AG concentration was not found to be correlated with the degree of obesity in both healthy subjects and diabetic patients. The plasma AG concentration showed a tendency to be higher in healthy males than in healthy females in all age-matched groups; however, statistically significant differences were not seen. Also, no significant influence of age was observed.

Key words

1,5-anhydro-D-glucitol 1-deoxyglucose polyol diabetic marker obesity uraemia age 


  1. 1.
    Pitkänen E (1973) Occurrence of 1,5-anhydroglucitol in human cerebrospinal fluid. Clin Chem Acta 48: 159–166Google Scholar
  2. 2.
    Servo C, Pitkänen E (1975) Variation in polyol levels in cerebrospinal fluid and serum in diabetic patients. Diabetologia 11: 575–580Google Scholar
  3. 3.
    Yamanouchi T, Akanuma H, Takaku F, Akanuma Y (1986) Marked depletion of plasma 1,5-anhydroglucitol, a major polyol, in streptozocin-induced diabetes in rats and the effect of insulin treatment. Diabetes 35: 204–209Google Scholar
  4. 4.
    Pitkänen E (1972) The serum polyol pattern and the urinary polyol excretion in diabetic and in uremic patients. Clin Chim Acta 38: 221–230Google Scholar
  5. 5.
    Akanuma Y, Ogawa K, Yamanouchi T, Mashiko Y, Oka K, Kosaka K, Akanuma H (1981) Decreased plasma 1,5-anhydroglucitol in diabetic patients. Diabetes 30 [Suppl 1]: 124AGoogle Scholar
  6. 6.
    Akanuma H, Ogawa K, Lee Y, Akanuma Y (1981) Reduced level of plasma 1,5-anhydroglucitol in diabetic patients. J Biochem 90: 157–162Google Scholar
  7. 7.
    Yoshioka S, Saitoh S, Negishi C, Fujisawa T, Fujimori A, Takatani O, Imura M, Funabashi M (1983) Variations of 1-deoxyglucose (1,5-anhydroglucitol) content in plasma from patients with insulin-dependent diabetes mellitus. Clin Chem 29: 1396–1398Google Scholar
  8. 8.
    Yamanouchi T, Akanuma H, Asano T, Konishi C, Akaoka I, Akanuma Y (1987) Reduction and recovery of plasma 1,5-anhydro-D-glucitol level in diabetes mellitus. Diabetes 36: 709–715Google Scholar
  9. 9.
    Servo C, Palo J, Pitkänen E (1977) Polyols in the cerebrospinal fluid and plasma of neurological, diabetic and uraemic patients. Acta Neurol Scandinav 56: 111–116Google Scholar
  10. 10.
    Pitkänen E (1982) Serum 1,5-anhydroglucitol in normal subjects and in patients with insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 42: 445–448Google Scholar
  11. 11.
    Niwa T, Yamamoto N, Maeda K, Yamada K, Ohki T (1983) Gas chromatographic-mass spectrometric analysis of polyols in urine and serum of uremie patients. J Chromatogr 277: 25–39Google Scholar
  12. 12.
    National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039–1057Google Scholar
  13. 13.
    WHO Expert Committee on Diabetes Mellitus (1980) Second report, Technical Report Series 646 GenevaGoogle Scholar
  14. 14.
    Hsieh S, Akanuma Y (1985) Instability of fasting blood glucose values in noninsulin-dependent diabetic patients with long-term insulin treatment. Metabolism 34: 371–376Google Scholar
  15. 15.
    Ohkubo A, Kamei S, Yamanaka M, Arai F, Kitajima M, Kondo A (1981) Plasma glucose concentrations of whole blood, as determined with a multilayer-film analytical element. Clin Chem 27: 1287–1290Google Scholar
  16. 16.
    Poulsen S, Billesbolle P, Kolendorf K, Thorsteinsson B (1985) The C-peptide response to glucagon injection in IDDM and NIDDM patients. Horm Metabol Res 17: 39–40Google Scholar
  17. 17.
    Pitkänen E, Pitkänen O (1984) The elimination of 1,5-anhydroglucitol administered to rats. Experientia 40: 463–465Google Scholar
  18. 18.
    Westervelt FB, Schreiner GE (1962) The carbohydrate intolerance of uremic patients. Ann Intern Med 57: 266–276Google Scholar
  19. 19.
    Spitz IM, Rubenstein AH, Bersohn I, Abrahams C, Lowy C (1970) Carbohydrate metabolism in renal disease. Quart J Med NS 39: 201–226Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • T. Yamanouchi
    • 1
  • H. Akanuma
    • 2
  • T. Nakamura
    • 3
  • I. Akaoka
    • 1
  • Y. Akanuma
    • 4
  1. 1.The Second Department of Internal MedicineUniversity of TeikyoJapan
  2. 2.Department of Chemistry, College of Arts and SciencesUniversity of TokyoJapan
  3. 3.Research Laboratories Pharmaceuticals GroupNippon Kayaku Co., Ltd.Japan
  4. 4.Institute for Diabetes Care and ResearchAsahi Life FoundationTokyoJapan

Personalised recommendations